Journal of Clinical Epidemiology
Volume 62, Issue 12 , Pages 1306-1315 , December 2009

Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model

  • Carl van Walraven

      Affiliations

    • Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author. F660-1053 Carling Avenue, Ottawa, Ontario, Canada. Tel: 613-761-4903; fax: 613-761-5355.
    • ,
  • Natalie Oake

      Affiliations

    • Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Doug Coyle

      Affiliations

    • Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    • Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Monica Taljaard

      Affiliations

    • Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Alan J. Forster

      Affiliations

    • Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada

,Accepted 28 January 2009.

References 

  1. Lesko L, Atkinson A. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347–366
  2. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485–502
  3. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In:  Nimmo WS,  Tucker GT editor. Clinical Measurement in Drug Evaluation. New York: J Wiley; 1995;p. 3–22
  4. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol. 1992;43(3):235–244
  5. Albert JM, Ioannidis JP, Reichelderfer P, Conway B, Coombs RW, Crane L, et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med. 1998;17(21):2435–2462
  6. Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003;60:253–260
  7. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339–344
  8. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal. Br J Clin Pharmacol. 1997;44(3):219–225
  9. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. 2002;39(9):1414–1421
  10. Ellenberg S, Hamilton J. Surrogate endpoints in clinical trials: cancer. Stat Med. 1989;8:405–413
  11. Morganti A. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes. J Am Soc Nephrol. 2006;17(4 Suppl. 2):S141–S144
  12. D'Agostino RB. Debate: the slippery slote of surrogate outcomes. Curr Control Trials Cardiovasc Med. 2000;1:76–78
  13. Cowles MK. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker. Stat Med. 2002;21(6):811–834
  14. Food and Drug Administration Moderization Act of 1997. Sec. 112. Expediting study and approval of fast track drugs. 1997.
  15. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997;16(13):1515–1527
  16. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992;11(2):167–178
  17. Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T, Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials. 2002;23:607–625
  18. Fleming T, DeMets D. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med. 1996;125(7):605–613
  19. Qu Y, Case M. Quantifying the indirect treatment effect via surrogate markers. Stat Med. 2006;25:223–231
  20. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001;57(4 Suppl. 1):205–212
  21. Biomarkers Definitions Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95
  22. Grimes D, Schulz K. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105(5 Pt 1):1114–1118
  23. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–788
  24. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–613
  25. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322(12):802–809
  26. Daniels MJ, Hughes MD, Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med. 1997;16(17):1965–1982
  27. Baker SG, Baker SG. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint. Biostatistics. 2006;7:58–70
  28. Oake N, Jennings A, Forster A, Fergusson D, Doucette S, van Walraven C. The association between anticoagulation intensity and outcomes for oral anticoagulant users: a systematic review and meta-analysis. Can Med Assoc J. 2008;179:235–244
  29. Fan X, Felsovalyi A, Sivo SA, Keenan SC. Generating univariate random numbers in SAS. SAS for Monte Carlo studies: a guide for quantitative researchers. Cary, NC: SAS Institute; 2001;25–59
  30. Graham PL, Mengersen K, Morton AP. Confidence limits for the ratio of two rates based on likelihood scores: non-iterative method. Stat Med. 2003;22(12):2071–2083
  31. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49(11):1215–1219
  32. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155–1166
  33. Sidhu P, O'Kane HO, Sidhu P, O'Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg. 2001;72(5):1523–1527
  34. Vadher B, Patterson DL, Leaning M, Vadher B, Patterson DL, Leaning M. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. Br Med J. 1997;314(7089):1252–1256
  35. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42–51
  36. Mitra R, Marciello MA, Brain C, Ahangar B, Burke DT, Mitra R, et al. Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital. Am J Phys Med Rehabil. 2005;84(6):423–427
  37. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431–440
  38. Hutten BA, Prins MH, Redekop WK, Tijssen JG, Heisterkamp SH, Buller HR. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost. 1999;82(4):1260–1263
  39. Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH, et al. Management of Chinese patients on warfarin therapy in two models of anticoagulation service—a prospective randomized trial. Br J Clin Pharmacol. 2006;62:601–609
  40. Menendez-Jandula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med. 2005;142:1–10
  41. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al. Self management of oral anticoagulation: randomised trial. Br Med J. 2005;331(7524):1057
  42. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE, et al. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med. 2000;160(15):2343–2348
  43. Wilson SJ-A, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Can Med Assoc J. 2003;169(4):293–298
  44. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol. 2003;3:16
  45. Holm T, Lassen JF, Husted SE, Christensen P, Heickendorff L, Holm T, et al. A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med. 2002;252(4):322–331
  46. Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H, et al. A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing. Br J Haematol. 2006;132:598–603
  47. Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol. 2002;55(11):845–849
  48. Shiach CR, Campbell B, Poller L, Keown M, Chauhan N, Shiach CR, et al. Reliability of point-of-care prothrombin time testing in a community clinic: a randomized crossover comparison with hospital laboratory testing. Br J Haematol. 2002;119(2):370–375
  49. Holm T, Lassen JF, Husted SE, Heickendorff L, Holm T, Lassen JF, et al. The quality of routine oral anticoagulant therapy in a large geographical area. A survey of 310,300 inhabitants. Dan Med Bull. 2002;49(3):252–255
  50. Laporte S, Quenet S, Buchmuller-Cordier A, Reynaud J, Tardy-Poncet B, Thirion C, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost. 2003;89(3):458–467
  51. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J. 2002;325(7372):1073–1075
  52. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–1026
  53. van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest. 2007;131:1508–1515
  54. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6(2):115–124
  55. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–639
  56. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84(5):805–810
  57. Pengo V, Legnani C, Noventa F, Palareti G. ISCOAT Study Group. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001;85(3):418–422
  58. Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother. 2005;39(3):446–451
  59. You JHS, Chan FWH, Wong RSM, Cheng C. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. Br J Clin Pharmacol. 2005;59:582–587
  60. Andersen PV, Aagaard J. Low-dose warfarin in patients with Carbomedics heart valve prostheses. Asian Cardiovasc Thorac Ann. 2000;8:11–14
  61. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305–1316
  62. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641–1647
  63. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998;82:433–437
  64. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967–973
  65. Haraldsson HM, Onundarson PT, Einarsdottir KA, Guomundsdottir BR, Petursson MK, Palsson K, et al. Performance of prothrombin-proconvertin time as a monitoring test of oral anticoagulation therapy. Am J Clin Pathol. 1997;107:672–680

PII: S0895-4356(09)00052-3

doi: 10.1016/j.jclinepi.2009.01.015

Journal of Clinical Epidemiology
Volume 62, Issue 12 , Pages 1306-1315 , December 2009

Article Tools

* Image Usage & Resolution